Cytiva

Cytiva (formerly GE Healthcare Life Sciences, acquired by Danaher) manufactures bioprocessing tools and consumables used in the production of biologics, vaccines, and cell and gene therapies at more than 90% of the world's top biopharma manufacturers. Its FlexFactory continuous bioprocessing platform emerged partly from collaborations with Lund University and University College London's biochemical engineering department. Cytiva co-funds university-based bioprocessing centers at MIT, ETH Zurich, and Chalmers University, seeding the next generation of upstream and downstream processing engineers. With the cell-and-gene therapy wave driving exponential demand for novel chromatography resins and hollow-fiber bioreactors, Cytiva is actively scouting academic labs pioneering perfusion culture and viral-vector purification — making it an important watch for academic-intelligence buyers in the life-science tools sector.